@all,
leider auf Englisch (aber es gibt ja Übersetzungsprogramme...) :
Abstinence or maintenance treatment in substance use disorders?Marc Walter and Michael Soyka
AddictionVolume 111, Issue 5, pages 775–776, May 2016
Auszug :
"Clearly, there is no direct alcohol agonist, probably because there is no single alcohol receptor and alcohol has a complex molecular mechanism of action, basically via different low-affinity biding sites. Interestingly, baclofen, which is viewed by some as a partial substitution for alcohol use disorder, acts as a γ-aminobutyric acid class B (GABA-B) receptor agonist. Some studies gave only mixed results compared to placebo [9].
Recently, however, baclofen has shown longer abstinence duration in a randomized controlled trial [10]. The drug has already been introduced into clinical practice in France and can very well be viewed as a partial agonist for the effects of alcohol.
To conclude, the agonist maintenance treatment may not be suitable for all drugs of abuse. A favourable agonist maintenance treatment requires good pharmacological potential, as well as suitable clinical and neurocognitive characteristics.
Effective pharmacological agents should be combined with effective psychosocial and psychotherapeutic treatment options in order to improve the therapeutic outcome of our patients. In most cases, improvement means good quality of life, good psychosocial functioning and a reduction in substance use."
Das klingt doch gar nicht so schlecht, oder ?
LG. Werner
